HLA-G Complex Tetramer Protein, Human (HEK293, His-Avi)

HLA-G is a nonclassical major histocompatibility class Ib molecule that is critical for immune regulation at the maternal-fetal interface. It cooperates with B2M to form a complex that selectively binds self-peptides to promote maternal-fetal tolerance by interacting with KIR2DL4, LILRB1, and LILRB2 receptors. HLA-G Complex Tetramer Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-G Protein and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and RIIPRHLQL peptide. HLA-G Complex Tetramer Protein, Human (HEK293, His-Avi), has molecular weight of 260-265 kDa.

HLA-G, a non-classical major histocompatibility class Ib molecule, plays a crucial role in immune regulation at the maternal-fetal interface. In association with B2M/beta-2 microglobulin, it forms a complex that selectively binds a limited repertoire of nonamer self-peptides derived from intracellular proteins, including histones and ribosomal proteins. This peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1, and LILRB2 receptors on uterine immune cells, fostering fetal development while maintaining maternal-fetal tolerance. Interactions with KIR2DL4 and LILRB1 receptors trigger NK cell senescence-associated secretory phenotype, promoting vascular remodeling and fetal growth during early pregnancy. Moreover, HLA-G's engagement with LILRB2 induces the differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, actively contributing to the maintenance of maternal-fetal tolerance. Additionally, HLA-G may play a role in balancing tolerance and antiviral immunity by modulating the effector functions of NK cells, CD8+ T cells, and B cells. Furthermore, it negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity, highlighting its multifaceted role in immune regulation at the maternal-fetal interface.

1. Serial dilutions of Anti-LILRB2 Antibody were added into Human HLA-G Tetramer, His Tag : Human LILRB2, mFc Tag binding reactioins. The half maximal inhibitiory concentration (IC₅₀) is ≤0.11 μg/mL.
2. Immobilized Human HLA-G Tetramer, His Tag at 0.5 μg/mL (100 μl/well) on the plate. Dose response curve for Anti-HLA-G Antibody, hFc Tag with the EC₅₀ of ≤10 ng/mL determined by ELISA.

Human

HEK293

C-Avi;C-8*His

P17693 (G25-T305)&P61769 (I21-M119)&RIIPRHLQL

3135  [NCBI]&567  [NCBI]

260-265 kDa

Greater than 95% as determined by Tris-Bis PAGE.

Lyophilized powder

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Normally 5% trehalose is added as protectant before lyophilization.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.